At BH Cellular Medicine, our doctors use your own cells from your bone marrow to prepare a final product that is injected into the affected area that naturally reduces inflammation and repairs damaged cells. This is called the “BMAC” procedure (Bone Marrow Aspirate Concentrate).
If you are seeking preventative and wellness treatments, BH Cellular Medicine uses your own cells (called ImPS™), which travel to areas of inflammation and regenerate into healthy cells to support overall wellness and healing.
If you are seeking treatment for a specific disease or condition, BH Cellular Medicine uses your own cells (called ImPS™ ) to target inflammation, regenerate healthy cells, and help alleviate symptoms.
301 N. Canon Drive, Suite 305
Beverly Hills, California 90210
© 2026 | BH Cellular Medicine | All Rights Reserved. All content and images are property of Cristina Bertolotto, MD and cannot be saved or duplicated without expressed written consent.
DISCLAIMER: The information provided on this website is for general educational purposes only and is not medical advice. Any references to cellular or regenerative approaches describe areas of ongoing scientific and clinical research. Except where specifically identified as an FDA‑approved product, the cellular procedures discussed on this website have not been evaluated or approved by the US Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease or condition. FDA has stated that stem cell products and products derived from adipose tissue of the type described here have not been approved to treat orthopedic, neurologic, cardiopulmonary, autoimmune, or other chronic conditions.(fda.gov)
Any cellular procedure carries potential risks, and benefits are uncertain. Decisions about care should be made in consultation with a licensed healthcare professional who can review all conventional and investigational options. BH Cellular Medicine endeavors to operate in compliance with applicable US laws and regulations governing human cells, tissues, and cellular and tissue‑based products (HCT/Ps), including requirements under section 361 of the Public Health Service Act and 21 CFR Part 1271, where applicable.(fda.gov)
PHOTO CITATION: Image source: Nature Reviews Endocrinology, March 2010 issue. File name: “NATURE-ENDOCRINOLGY-BH-CELLULAR-1920px.png”.
